

ACORDA THERAPEUTICS INC  
Form 8-K  
August 21, 2013

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): August 16, 2013

Acorda Therapeutics, Inc.  
(Exact name of registrant as specified in its charter)

Delaware  
(State or other jurisdiction  
of incorporation)

000-50513  
(Commission  
File Number)

13-3831168  
(I.R.S. Employer  
Identification No.)

420 Saw Mill River Road,  
Ardsley, NY  
(Address of principal  
executive offices)

10502  
(Zip Code)

Registrant's telephone number, including area code: (914) 347-4300

Not Applicable

Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01                      Other Events

In August 2013, Ron Cohen, M.D., President and CEO of Acorda Therapeutics, Inc. (“Acorda”), exercised 289,778 stock options, all of which were due to expire in September and October of this year unless exercised. Dr. Cohen sold 149,000 of the resultant shares, the proceeds of which are being used to fund the exercise of the options and the resulting tax liability. A record of all of Dr. Cohen’s holdings is available in Acorda’s SEC filings. Dr. Cohen retains the majority of the equity he has been granted in the Company since founding Acorda in 1995.

The stock sales were made pursuant to a previously established 10b5-1 plan.

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Acorda Therapeutics, Inc.

August 20, 2013

By: /s/David Lawrence  
Name: David Lawrence  
Title: Chief Financial Officer